|
Synonyms: CSF-1 | lanimostim | macrophage-CSF
Compound class:
Endogenous peptide in human, mouse or rat
Comment: M-CSF (CSF1) controls survival and differentiation of macrophages via activation of the CSF1 receptor (a receptor tyrosine kinase). The biologically active peptide is a homodimer or a heterodimer.
Pharmacological modulators of the CSF1/CSF1R axis, targeting tumour-associated macrophage (TAM) survival, are being developed for various solid tumour and hematological oncology indications as well as for autoimmune diseases.
Species: Human
|
| No information available. |
Summary of Clinical Use  |
| An eye drop formulation containing CSF1 (PresbiDrops; Orasis Pharmaceuticals) is in clinical development for presbyopia, an age-related condition that causes long-sightedness. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT02965664 | Safety, Tolerability and Efficacy of PresbiDrops (CSF-1) in Presbyopic Subjects | Phase 2 Interventional | Orasis Pharmaceuticals Ltd. | ||
| NCT03885011 | A Multi-Center, Double-Masked Evaluation of the Efficacy and Safety of CSF-1 in the Treatment of Presbyopia | Phase 2 Interventional | Orasis Pharmaceuticals Ltd. | ||
